DexCom, Inc. (NASDAQ:DXCM) target price raised to $97.00, reported today by B. Riley
- Updated: September 26, 2016
DexCom, Inc. (NASDAQ:DXCM) had its stock price target increased to $97.00 by B. Riley in a report released Monday September 26, 2016. The new stock price target indicates a possible upside of 0.04% from the company's most recent stock price close.
Having a price of $93.26, DexCom, Inc. (NASDAQ:DXCM) traded -0.80% lower on the day. With the last stock price up 21.70% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. DXCM has recorded a 50-day average of $92.05 and a two hundred day average of $76.55. Volume of trade was down over the average, with 446,770 shares of DXCM changing hands under the typical 778,438
Recent Performance Chart
DexCom, Inc. has 52 week low of $47.92 and a 52 week high of $96.38 and has a market cap of $0.
General Information About DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and a mobile application on the patient's iPhone to transmit glucose information.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.